According to a study published in RMD Open, antiphospholipid antibodies are associated with a significantly higher risk of adverse pregnancy outcomes in women with systemic lupus erythematosus, with specific antibody combinations carrying markedly greater risks than others.
Antibody Profiles and Pregnancy Risk in Lupus Cohorts
Systemic lupus erythematosus predominantly affects women of childbearing age and frequently complicates pregnancies. While antiphospholipid antibodies are recognized risk factors in the general population and appear at higher rates in lupus patients, researchers note that the precise impact of varying antibody profiles remained largely uninvestigated until now. To address this gap, investigators at a single center in China evaluated profiles including anticardiolipin antibodies, anti-β2 glycoprotein I antibodies, and lupus anticoagulant across 441 pregnancies between January 2013 and January 2024, as detailed in the additional reporting from rmdopen.bmj.com.
Out of 441 total pregnancies tracked in the cohort, 78 cases (17.9%) tested positive for antiphospholipid antibodies. Adverse pregnancy outcomes—defined by the study as prefetal death, fetal death, or severe pre-eclampsia and placental insufficiency occurring prior to 34 weeks of gestation—occurred in 71 pregnancies, or 16.1%. Live births were achieved in 391 pregnancies, representing 88.7% of the total cohort.
Clinical Insight: According to the findings, positive antiphospholipid antibodies were linked to significantly more frequent adverse outcomes at 29.5% compared to just 13.2% in antibody-negative patients (p=0.002). Furthermore, positivity drove a higher risk of fetal death (p=0.021) and failure of live birth (p=0.011).
High-Risk Combinations: Lupus Anticoagulant and IgG Isotypes
Not all antibody profiles carry equal danger for pregnant patients managing systemic lupus erythematosus. The study established that specific isotypes and combinations drastically elevate obstetric hazards. The research data revealed that significantly heightened risks were independently linked to anticardiolipin IgG (p=0.003), anti-β2 glycoprotein I IgG (p=0.020), and lupus anticoagulant (p=0.002). Conversely, the corresponding IgM antibodies showed no significant associations with poor pregnancy results.
In terms of combined profiles, the data showed that the highest-risk profile (p=0.002) consisted of lupus anticoagulant accompanied by IgG isotypes of anticardiolipin and/or anti-β2 glycoprotein I. Other evaluated combinations showed no statistically significant association, registering at p=0.128. These distinctions allow clinicians to move beyond simple binary testing and focus on targeted risk stratification for patients carrying high-risk antibody combinations.
Mechanisms of Placental Injury and Trophoblast Disruption
Understanding how antiphospholipid antibodies mediate adverse pregnancy outcomes involves examining cellular disruptions within the placenta. According to mechanistic studies cited in the RMD Open data, these antibodies exert various adverse effects directly on trophoblast cells. Serum from patients with positive antiphospholipid antibodies can inhibit placental growth and induce trophoblastic apoptosis. Additionally, anti-β2 glycoprotein I antibodies inhibit cytotrophoblast cell fusion via toll-like receptor 4 (TLR4), a process that can be reversed by blocking TLR4.
Additional cellular impacts include the downregulation of trophoblast interleukin-6 (IL-6) secretion by anti-β2 glycoprotein I antibodies, which diminishes STAT3 activation and subsequently halts cell migration. These antibodies also perturb the secretion of trophoblast angiogenic factors—elevating vascular endothelial growth factor, placenta growth factor, and soluble endoglin—which interferes with normal vascular development and remodeling. Finally, antiphospholipid antibodies activate the complement system, promoting complement deposition that drives placenta injuries such as deciduitis, villous infarcts, and decidual vasculopathy.
Did You Know? The prevalence of antiphospholipid antibody positivity in the Chinese cohort was lower than rates reported in general systemic lupus erythematosus populations, but remained comparable to figures seen in other studies focused specifically on pregnant patients with lupus, according to the published research.
Frequently Asked Questions
What are the primary adverse pregnancy outcomes associated with lupus and antiphospholipid antibodies?
Adverse outcomes defined by the study include prefetal death, fetal death, severe pre-eclampsia, and placental insufficiency occurring before 34 weeks of gestation.
Which specific antibody profile carries the highest obstetric risk?
According to the research, lupus anticoagulant combined with IgG isotypes of anticardiolipin and/or anti-β2 glycoprotein I antibodies represents the highest-risk profile.
Did IgM antibodies show the same level of risk as IgG antibodies?
No. While anticardiolipin IgG and anti-β2 glycoprotein I IgG were significantly associated with increased risk, their corresponding IgM antibodies were not found to be significantly associated with adverse outcomes.
Can these findings establish direct causality?
Because the investigation was a retrospective cohort study, the authors noted that causality cannot be definitively established, though the findings strongly emphasize the necessity of advanced risk stratification.
Stay Informed on Clinical Research
Explore our latest coverage of rheumatology, maternal-fetal medicine, and peer-reviewed studies. Share your thoughts in the comments below or subscribe to receive clinical updates directly.